Controlled Nicorandil Administration for Myocardial Protection During Coronary Artery Bypass Grafting Under Cardiopulmonary Bypass
Authors:
- Yoshiki SawaYSYoshiki Sawa
- Shigeaki OhtakeSOShigeaki Ohtake
- Motonobu NishimuraMNMotonobu Nishimura
- Hajime IchikawaHIHajime Ichikawa
- Hikaru MatsudaHMHikaru Matsuda
- 1 July 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 38 (1) , 21-28
Abstract
Nicorandil is a hybrid potassium channel opener, and recent experimental studies have demonstrated its efficacy in myocardial protection against ischemia-reperfusion. This clinical study was designed to examine the myocardial protective effect of nicorandil administered during cardiopulmonary bypass. Seventy adult patients, 53 men and 17 women, undergoing elective coronary artery bypass grafting were randomly assigned to two groups, one receiving nicorandil during cardiopulmonary bypass (group N, n = 35) and the other receiving no nicorandil for control (group C, n = 35). Nicorandil was administered at each dose of 0.1 mg/kg into the cardiopulmonary bypass circuit according to the following schedule: (1) bolus injection at the initiation of cardiopulmonary bypass, (2) continuous infusion for 5 min before aortic cross-clamping, (3) bolus administration at 5 min before reperfusion, and (4) continuous infusion for 5 min before reperfusion. The time required for achieving cardiac arrest after the initial cardioplegia was significantly reduced in group N in comparison with that in group C. After aortic unclamping, the number of patients showing a significant ST segment change on the electrocardiogram was significantly fewer in group N, whereas the number of patients showing spontaneous recovery of heart beat was significantly greater. As for the myocardial protective effect, group N showed lower plasma levels of malondialdehyde, human-heart fatty acid-binding protein, and peak creatine kinase-MB, and required lower doses of catecholamine. Our results suggest that nicorandil administration during cardiopulmonary bypass provides enhanced myocardial protective effects against ischemia-reperfusion in patients undergoing coronary artery bypass grafting.Keywords
This publication has 26 references indexed in Scilit:
- Myocardial Protection Afforded by Nicorandil and Ischaemic Preconditioning in a Rabbit Infarct Model In VivoJournal of Cardiovascular Pharmacology, 1998
- Ischaemic preconditioning may abolish the protection afforded by ATP-sensitive potassium channel openers in isolated human atrial muscleBasic Research in Cardiology, 1997
- Potassium channel openers prevent potassium-induced calcium loading of cardiac cells: Possible implications in cardioplegiaThe Journal of Thoracic and Cardiovascular Surgery, 1996
- Vasodilatory Effect of Nicorandil on Coronary Arterial MicrovesselsJournal of Cardiovascular Pharmacology, 1995
- Protective effect of nicorandil as an additive to the solution for continuous warm cardioplegiaThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Activation of ATP-dependent K+ channels enhances myocardial protection due to cold high potassium cardioplegia: A force-frequency relationship studyJournal of Molecular and Cellular Cardiology, 1995
- NicorandilDrugs, 1992
- Effect of nicorandil on coronary spasmThe American Journal of Cardiology, 1989
- Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary ArteriesNew England Journal of Medicine, 1986
- Coronary-Artery Spasm Immediately after Myocardial RevascularizationNew England Journal of Medicine, 1981